Antimicrobial resistance is projected to cause more annual deaths than cancer by 2050 [1].
This trend threatens to destabilize global healthcare systems and the rest of the economy as common infections become untreatable. The rise of "superbugs" creates a cycle of increasing mortality and escalating costs for medical interventions.
Japanese pharmaceutical experts said that antibiotic resistance is a major threat to health and the economy [1]. These experts highlighted the danger of a "broken market" where the development of new treatments fails to keep pace with the evolution of resistant bacteria.
The economic impact of this crisis is reflected in the growth of diagnostic and treatment sectors. The global antibiotic resistance market is projected to reach USD 17.8 billion by 2033, growing at a compound annual growth rate of 5.3% [3].
In the U.S., the need for specialized testing is increasing. The antimicrobial susceptibility testing market in the U.S. is expected to reach USD 1.8 billion by 2035 [2]. This growth is driven by a combination of diagnostic innovation, and the rising prevalence of antimicrobial resistance.
Experts said the current trajectory leads to a future where routine surgeries and minor injuries could once again become fatal. The shift toward more expensive, specialized testing is a response to the fact that standard antibiotics are losing their efficacy against evolving pathogens [1], [2].
“"Antibiotic resistance is a major threat to our health and economy."”
The convergence of rising mortality projections and expanding market values for susceptibility testing suggests a shift in global medicine. As traditional antibiotics fail, the healthcare industry is pivoting toward high-cost, precision diagnostics to identify specific resistant strains, reflecting a transition from broad-spectrum treatment to a more expensive, targeted model of care.
